Cytochrome P450 (CYP) inhibition screening: Comparison of three tests

被引:41
|
作者
Turpeinen, Miia
Korhonen, Laura E.
Tolonen, Ari
Uusitalo, Jouko
Juuonen, Risto
Raunio, Hannu
Pelkonen, Aui
机构
[1] Univ Oulu, Dept Pharmacol & Toxicol, Oulu 90014, Finland
[2] Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland
[3] Novamass Analyt Ltd, Oulu, Finland
关键词
cytochrome P450 (CYP); inhibition; human liver microsomes; recombinant enzymes; in vitro cocktail; fluorescent probes; sotalol; propranolol; citalopram; fluoxetine; oxazepam; diazepam;
D O I
10.1016/j.ejps.2006.06.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There are several different experimental systems for screening of in vitro inhibitory potency of drugs under development. In this study we compared three different types of cytochrome P450 (CYP) inhibition tests: the traditional single substrate assays, the fluorescent probe method with recombinant human CYPs, and a novel n-in-one technique. All major hepatic drug-metabolizing CYPs were included (1A2, 2A6, 2136, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4). Six compounds (sotalol, propranolol, citalopram, fluoxetine, oxazepam and diazepam) were selected for detailed comparisons. The IC50 values of each of these compounds were measured using the three assay types. The inhibitory potencies of these model drugs were generally within the same order of magnitude and followed similar inhibition profiles in all the assay types. Clinically observed inhibitory interactions, or lack thereof, were predictable with all three assays. Comparison of potencies of 'diagnostic' inhibitors revealed also some notable differences between the assays, especially regarding CYP2E1. The potency of inhibitors towards CYP3A4 was dependent on the substrate and reaction measured. Generally all three assays gave reasonably comparable results, although some unexplained differences were also noted (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:130 / 138
页数:9
相关论文
共 50 条
  • [31] Cytochrome P450 (CYP450) genotyping on the CodeLink™ bioarray.
    Longenbach-Huber, S
    Safgren, S
    Raich, T
    George, J
    Ames, MA
    O'Kane, DJ
    CLINICAL CHEMISTRY, 2001, 47 (11) : 2085 - 2085
  • [32] Measurement of cytochrome P450 and NADPH–cytochrome P450 reductase
    F Peter Guengerich
    Martha V Martin
    Christal D Sohl
    Qian Cheng
    Nature Protocols, 2009, 4 : 1245 - 1251
  • [33] Metabolic activation and cytochrome P450 inhibition of piperlonguminine mediated by CYP3A4
    Chi, Yuqian
    Zhu, Xiaoliang
    Chen, Yaxuan
    Li, Xin
    Jiang, Ziyi
    Jian, Xiaoyang
    Lian, Mengyuan
    Wu, Xiaodi
    Wang, Lei
    Sun, Mengmeng
    Shi, Xiaowei
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 268
  • [34] Expression, Function and Regulation of Mouse Cytochrome P450 Enzymes: Comparison With Human Cytochrome P450 Enzymes
    Hrycay, E. G.
    Bandiera, S. M.
    CURRENT DRUG METABOLISM, 2009, 10 (10) : 1151 - 1183
  • [35] In vitro screening of cytochrome P450 induction potential
    Pelkonen, O
    Hukkanen, J
    Honkakoski, P
    Hakkola, J
    Viitala, R
    Raunio, H
    PHARMACOKINETIC CHALLENGES IN DRUG DISCOVERY, 2002, 37 : 105 - 137
  • [36] Inhibition of Cytochrome P450 Enzymes by Quinones and Anthraquinones
    Sridhar, Jayalakshmi
    Liu, Jiawang
    Foroozesh, Maryam
    Stevens, Cheryl L. Klein
    CHEMICAL RESEARCH IN TOXICOLOGY, 2012, 25 (02) : 357 - 365
  • [37] Miniaturization and automation of cytochrome P450 inhibition assays
    Marks, Bryan D.
    Larson, Brad
    DRUG METABOLISM REVIEWS, 2006, 38 : 61 - 62
  • [38] Irreversible inhibition of cytochrome P450 by nitric oxide
    Minamiyama, Y
    Takemura, S
    Imaoka, S
    Funae, Y
    Tanimoto, Y
    Inoue, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, 283 (03): : 1479 - 1485
  • [39] Inhibition of cytochrome p450 enzymes by nitric oxide
    Stadler, J
    Schmalix, WA
    Doehmer, J
    BIOLOGICAL REACTIVE INTERMEDIATES V: BASIC MECHANISTIC RESEARCH IN TOXICOLOGY AND HUMAN RISK ASSESSMENT, 1996, 387 : 187 - 193
  • [40] Inhibition and Induction of Cytochrome P450 and the Clinical Implications
    Jiunn H. Lin
    Anthony Y. H. Lu
    Clinical Pharmacokinetics, 1998, 35 : 361 - 390